arrow
E

Electra Nicolaidou

Andreas Sygros Hospital for Skin and Venereal Diseases
H指数:24
被引数:2,044

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failure

比美基zumab、古塞库zumab和利萨基zumab在二级IL-17抑制剂失败后的药物生存率

2026-06-160
PRE
Real-World, Prospective, Multicenter Outcomes to Brodalumab Treatment in Patients With Moderate-to-Severe Psoriasis in Greece (The RESOLVE Study)

希腊中度至重度银屑病患者接受Brodalumab治疗的现实世界、前瞻性、多中心研究结局(RESOLVE研究)

2026-02-010
OAAI
Long-term effectiveness, safety and prognostic factors of response to treatment with bimekizumab in patients with plaque psoriasis: results from a real-world multicentre study

长期疗效、安全性及对布美其单抗治疗反应的预后因素:一项真实世界多中心研究的结果

2025-12-010
PRE
Long-Term Outcomes of Guselkumab and Risankizumab for the Management of Moderate-to-Severe Psoriasis in the Elderly: Results from a Real-World Retrospective Study

老年中重度银屑病患者使用古塞库单抗和 risankizumab 管理的长期疗效:真实世界回顾性研究的结果

2025-10-010
OAAI
A 30-Year Epidemiological Study of Opportunistic Fungal Infections in People Living with HIV in Greece: Associations with Demographic Characteristics and Immune Status

希腊艾滋病病毒感染者机会性真菌感染的30年流行病学研究:与人口统计学特征和免疫状况的关联

2025-08-230
PRE
Guselkumab Is Effective for the Management of Scalp Psoriasis in Both Biologic-Naïve and Biologic-Experienced Patients: Results From a Real-World, Retrospective Study

Guselkumab在生物制剂初治和生物制剂经治患者中均对头皮银屑病的管理有效:一项真实世界回顾性研究的结果

2025-06-040
PRE
Real-world effectiveness and drug survival of guselkumab over a period of 3 years in moderate-to-severe plaque psoriasis, including difficult-to-treat areas
2024-07-251
OA